ArticleNPJ precision oncology2026

Targeting the CHD3 chromatin remodeler exploits a synthetic lethal vulnerability in dual SMARCA4/SMARCA2-deficient cancers via derepression of PARD3B.

Mariko Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.